Anavex Life Sciences Earnings Preview

Anavex Life Sciences (NASDAQ:AVXL) is set to give its latest quarterly earnings report on Wednesday, 2024-02-07. Here’s what…

Anavex Life Sciences (NASDAQ:AVXL) is set to give its latest quarterly earnings report on Wednesday, 2024-02-07. Here’s what investors need to know before the announcement.

Analysts estimate that Anavex Life Sciences will report an earnings per share (EPS) of $-0.14.

Anavex Life Sciences bulls will hope to hear the company announce they’ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Past Earnings Performance

Last quarter the company beat EPS by $0.03, which was followed by a 6.6% increase in the share price the next day.

Here’s a look at Anavex Life Sciences’s past performance and the resulting price change:

Quarter Q4 2023 Q3 2023 Q2 2023 Q1 2023
EPS Estimate -0.15 -0.17 -0.19 -0.19
EPS Actual -0.12 -0.14 -0.17 -0.17
Price Change % 6.6% 16.69% 3.2% -6.98%

eps graph

Stock Performance

Shares of Anavex Life Sciences were trading at $5.36 as of February 05. Over the last 52-week period, shares are down 49.18%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release.

To track all earnings releases for Anavex Life Sciences visit their earnings calendar on our site.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Cannabis Company 4Front Reports 28% YoY Drop In Q1 Revenue While Net Loss Grows, CEO Optimistic With Biden’s Marijuana Rescheduling News

Vertically integrated multi-state cannabis operator and retailer 4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) announced on Friday its results for the quarter ended March 31, 2024. "We've had an encouraging start to the year, energized by the fresh dynamics introduced with my recent appointment as CEO," the company's Andrew Thut said. "In just a few weeks, we've seen tangible improvements in our financial health, evidenced by reduced operational costs and effective management of working capital."

CSE:FFNT